Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis
This study has been completed.
Study NCT00004786   Information provided by Office of Rare Diseases (ORD)
First Received: February 24, 2000   Last Updated: June 23, 2005   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Systemic Sclerosis
Raynaud Disease
Additional conditions recognized in this trial
Scleroderma, Diffuse
Scleroderma, Systemic
Sclerosis
More general conditions related to this trial
Cardiovascular Diseases
Connective Tissue Diseases
Pathologic Processes
Peripheral Vascular Diseases
Skin Diseases
Vascular Diseases
Interventions listed in this trial
iloprost
More general drug interventions related to this trial
Cardiovascular Agents
Hematologic Agents
Pharmacologic Actions
Platelet Aggregation Inhibitors
Therapeutic Uses
Vasodilator Agents
Sponsors listed in this trial
National Center for Research Resources (NCRR)
University of Pittsburgh


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services